Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGF401 in advanced HCC and solid tumors
NCT02325739Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of roblitinib in hepatocellular carcinoma (HCC) and solid tumor, sponsored by Novartis. Primary endpoints: Dose-limiting Toxicity, Time to Progression up to 4.5 years and 1 more. Started Dec 2014; status: completed.
02
Drugs
roblitinib
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT02325739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325739.